AC
ACAD icon

AXQ Capital’s Acadia Pharmaceuticals ACAD Stock Holding History

AXQ Capital’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-19,680
Closed -$320K – 416
2024
Q2 		$320K Buy
19,680
+2,901
+17% +$46.8K 0.07% 358
2024
Q1 		$310K Buy
16,779
+8,278
+97% +$205K 0.07% 422
2023
Q4 		$266K Sell
8,501
-11,050
-57% -$264K 0.07% 416
2023
Q3 		$407K Buy
+19,551
New +$531K 0.14% 242
2023
Q2 		– Sell
-12,339
Closed -$232K – 264
2023
Q1 		$232K Buy
+12,339
New +$235K 0.09% 372

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

AXQ Capital's ACAD Position: Q3 2024 in Review

AXQ Capital sold out of Acadia Pharmaceuticals (ACAD) in Q3 2024, closing a stake of 19,680 shares — an estimated $320K sold.

AXQ Capital first reported a position in ACAD in Q1 2023 and held it in 5 quarters. The position peaked at $407K in Q3 2023. 256 funds tracked by Wall St. Rank hold ACAD as of Q3 2024.

  • AXQ Capital reported no remaining Acadia Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • AXQ Capital sold 19,680 Acadia Pharmaceuticals shares in Q3 2024, an estimated $320K.
  • AXQ Capital first reported a position in Acadia Pharmaceuticals in Q1 2023 and held it in 5 quarters.
  • AXQ Capital's Acadia Pharmaceuticals position peaked at $407K in Q3 2023.
  • 256 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2024.

Based on AXQ Capital's 13F filing for Q3 2024, filed 14 Nov 2024.